Leproust Emily M. sold $3.2M of TWST
Leproust Emily M. (Chief Executive Officer) sold 49,299 shares of Twist Bioscience Corp (TWST) at an average of $65.19 ($65.08–$66.28, $3.21M total) across 3 trades over 2026-05-26 to 2026-05-27 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the record of insider activity but does not introduce new guidance, contracts, litigation, or operational developments.
Market read
Traders may monitor insider activity for sentiment, but this specific event is routine and pre-arranged, limiting actionable signal.
What to watch
The filing does not disclose reasons for the sale, and the price range ($65.08 to $66.28) may reflect scheduled execution rather than valuation views.
Background
The article is an SEC Form 4 insider transaction disclosure for Twist Bioscience, filed by the CEO.
Ticker impact
Twist Bioscience CEO Emily M. Leproust sold about 49,299 shares in open-market trades under a 10b5-1 plan for roughly $3.21M total value.
Likely limited near-term impact; any effect would be sentiment-only unless paired with other disclosures.
The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific fundamentals or guidance changes.
Market effects
No direct sector read-through; insider sales under 10b5-1 are generally not a sector signal.
None indicated.
None indicated.
Counterpoint
Insider sales can be interpreted as diversification rather than bearish expectations, especially when executed under a 10b5-1 plan.
Key entities
- issuerTwist Bioscience Corp
Subject of the Form 4 insider sale by its CEO under a 10b5-1 plan.
- insiderEmily M. Leproust
CEO and director who sold shares in open-market transactions.
